Eversheds says Sun Pharmaceuticals deal represents opportunity in generics market
Eversheds partner Richard Lewis has commented on Sun Pharmaceuticals’ acquisition of Ranbaxy.
Lewis said: ‘This deal is a clear sign of further consolidation in the Indian generics market as companies look to increase market share, enhance growth opportunities and reduce costs.
‘As the country’s largest pharma company, it will now be particularly well placed to capitalise on the fast-growing Indian pharmaceuticals market.’
News from Eversheds
News from The Lawyer
Briefings from Eversheds
European Commission proposes reforms to merger control regime; how will this affect the aviation sector?
The European Commission has produced a white paper setting out proposals to improve and extend European Union merger control.
The potential impact of Ebola is of interest to all corporations with a presence in Africa, and in particular to those with projects, assets and personnel in the countries affected.
Analysis from The Lawyer
A new breed of lawyer is smoothing the path for companies entering emerging or unstable jurisdictions
‘Exotic’ investors and opportunities for legal work beyond M&A feature in The Lawyer’s high-level roundtable debate on south-east Europe